Creative Biolabs rAb Blog

Menu

Skip to content
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News

Category Archives: Therapeutic Antibody R&D

Astellas Claudin18.2 Antibody Phase III Clinical Trial—Primary Endpoint Reached!

November 18, 2022News, Therapeutic Antibody R&DClaudin18.2, Zolbetuximabbiorab

Astellas recently announced positive top-line results of the Phase III SPOTLIGHT clinical trial designed to evaluate the efficacy and safety of zolbetuximab in combination with mFOLFOX6—a combination regimen including oxaliplatin, calcium folinate,Read More…

An Optimal Combination Therapy with Broadly Neutralizing Antibodies Shows Promise in Stopping HIV Escape and Rebound

October 14, 2022Recombinant Antibody R&D, Therapeutic Antibody R&Dtherapeutic antibodybiorab

In a recently published study, researchers from the Max Planck Institute for Dynamics and Self-Organization in Germany, the University of Cologne, and the University of Washington found that a carefully designed mixtureRead More…

European Commission Approved Long-Acting Antibody Therapy Evusheld for the Treatment Against COVID-19

October 1, 2022Therapeutic Antibody R&Dtherapeutic antibodybiorab

AstraZeneca recently announced that the European Commission (EC) has approved its long-acting antibody therapy Evusheld (tesaglizumab in combination with cilgravizumab, formerly AZD7442) for the treatment of adults and adolescents with severe COVID-19Read More…

Pattern and Trend of Therapeutic Antibody Discovery

July 15, 2021Antibody Engineering R&D, Therapeutic Antibody R&Dantibody discovery, therapeutic antibodybiorab

Since the first therapeutic antibody Muromonab-CD3 was approved in 1986, more than 100 antibodies have been approved for marketing. Based on their properties, antibodies can be divided into four categories: mouse antibodies,Read More…

Nine characteristics shared by the most successful mAb

February 1, 2019News, Therapeutic Antibody R&Dantibody discovery, monoclonal antibody drug, therapeutic antibodybiorab

The path to finding a therapeutic antibody that leads to significant medical improvements is often complicated, long, and costly. Many criteria have to be taken into account in order to begin theRead More…

Sixteen New Tumor Drugs First Approved in 2018

December 28, 2018News, Therapeutic Antibody R&Dantibody discovery, therapeutic antibodybiorab

In 2018, from the approval of JNJ’s apalutamide in the United States on February 14 to that of larotrectinib on November 26, a total of 16 new tumor drugs were approved forRead More…

Nat Genet:Scientists Discover New Target for Immunotherapy Following 2018 Nobel Prize for Medicine

December 20, 2018News, Therapeutic Antibody R&Dantibody discovery, immunotherapy, monoclonal antibody drug, therapeutic antibodybiorab

Following the 2018 Nobel Prize for Medicine, global attention is now more than ever turned toward the promise of immunotherapy in oncology. According to a recent study published in the international journalRead More…

The First Rituxan Biosimilar Is Expected to Be Approved by FDA

October 25, 2018News, Therapeutic Antibody R&Dantibody discovery, monoclonal antibody drug, Rituximab, therapeutic antibodybiorab

B cell lymphoma is a solid tumor that occurs in B cells, including Hodgkin’s lymphoma and non-Hodgkin’s lymphoma. In numerous types of B cell lymphoma, classic Hodgkin’s lymphoma and nodular lymphocyte areRead More…

First Approval for Fremanezumab-vfrm

September 27, 2018News, Therapeutic Antibody R&Dantibody discovery, monoclonal antibody, monoclonal antibody drug, therapeutic antibodybiorab

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AJOVYTM (fremanezumab-vfrm) injection for the preventive treatment of migraine in adults. AJOVY, aRead More…

Antibody Combo Knocks Down HIV in Clinical Trials

September 27, 2018News, Therapeutic Antibody R&Dantibody combination, blocking antibody, hiv immunology, monoclonal antibody, monoclonal antibody drug, therapeutic antibodybiorab

A mix of two monoclonal antibodies against HIV tamped down virus levels in patients not taking antiretroviral medication, according to the results of two early-stage clinical trials reported in nature. After several infusionsRead More…

Posts navigation

  • 1
  • 2
  • Next »

Categories

  • Antibody Engineering R&D
  • Cancer Immunotherapy
  • News
  • Recombinant Antibody R&D
  • Therapeutic Antibody R&D

Recent Posts

  • Scientists Reviewed the Advances, Challenges and Countermeasures in Immunotherapy of Gastrointestinal Tumors
  • Released! Mechanisms Behind Immune Cells’ Responses to Cancer Cell Mutations
  • The Ineffectiveness of Cancer Immunotherapy May Be Due to the Lack of Specific Key Immune Cells in Patients
  • Scientists Discovered the Key Molecule Triggering Cancer Metastasis
  • Transcriptional and Immunophenotypic Profiling Reveals Molecular and Immunological Features of Cancer Tumourigenesis

Archives

Contact Us

USA – UK

Copyright © Creative Biolabs rAb Blog
Powered by WordPress , Designed and Developed by templatesnext